Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
Danuta M. Skowronski, Macy Zou, Suzana Sabaiduc, Michelle Murti, Romy Olsha, James A. Dickinson, Jonathan B. Gubbay, Matthew A. Croxen, Hugues Charest, Agatha N. Jassem, Mel Krajden, Nathalie Bastien, Yan Li, Gaston De Serres
Abstract
Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.
Topics & Concepts
InterimConfidence intervalMedicineVirologyInfluenza vaccineInfluenza seasonHuman influenzaCirculation (fluid dynamics)VirusCoronavirus disease 2019 (COVID-19)Internal medicineGeographyDiseaseInfectious disease (medical specialty)PhysicsThermodynamicsArchaeologyInfluenza Virus Research StudiesRespiratory viral infections researchCOVID-19 epidemiological studies